Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Wenzel

Showing results (21-30 of 213) with videos related to

Pageof 22
Sort By:
The Prostate|June 8, 2021
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table dataChristoph Würnschimmel, Mike Wenzel, Nuowei Wang, et al.
Urologic Oncology|June 7, 2021
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume centerChristoph Würnschimmel, Mike Wenzel, Nuowei Wang, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|December 4, 2020
Influence of an Early Application of Mammalian Target of Rapamycin Inhibitors Everolimus and Sirolimus on Acute Vascular Inflammatory Responses After Ischemia-Reperfusion InjuryMike Wenzel, Henryk Haffer, Pengfei Wang, et al.
Urologia Internationalis|February 7, 2024
Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic SurveySilvan Sigg, Winfried Arnold, Nico Christian Grossmann, et al.
European Urology|June 24, 2021
Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European CohortChristoph Würnschimmel, Randi Marisa Pose, Mike Wenzel, et al.
Prostate International|October 25, 2021
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancerFelix Preisser, Felix K-H Chun, Severine Banek, et al.
Urologie (Heidelberg, Germany)|December 21, 2023
[First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer]Mike Wenzel, Benedikt Hoeh, Jan Kasparek, et al.
Urologie (Heidelberg, Germany)|May 19, 2026
[Artificial intelligence in daily urological care: results of the AI barometer]Nicolas Carl, Frederik Wessels, Jonathan Jeutner, et al.
European Urology Open Science|June 17, 2025
Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate CancerMike Wenzel, Thomas Steuber, Carolin Siech, et al.
European Urology Focus|September 4, 2022
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysisPhilipp Mandel, Benedikt Hoeh, Mike Wenzel, et al.
Pageof 22

Showing results (21-30 of 213) with videos related to

Sort By:
Pageof 22
The Prostate|June 8, 2021
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table dataChristoph Würnschimmel, Mike Wenzel, Nuowei Wang, et al.
Urologic Oncology|June 7, 2021
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume centerChristoph Würnschimmel, Mike Wenzel, Nuowei Wang, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|December 4, 2020
Influence of an Early Application of Mammalian Target of Rapamycin Inhibitors Everolimus and Sirolimus on Acute Vascular Inflammatory Responses After Ischemia-Reperfusion InjuryMike Wenzel, Henryk Haffer, Pengfei Wang, et al.
Urologia Internationalis|February 7, 2024
Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic SurveySilvan Sigg, Winfried Arnold, Nico Christian Grossmann, et al.
European Urology|June 24, 2021
Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European CohortChristoph Würnschimmel, Randi Marisa Pose, Mike Wenzel, et al.
Prostate International|October 25, 2021
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancerFelix Preisser, Felix K-H Chun, Severine Banek, et al.
Urologie (Heidelberg, Germany)|December 21, 2023
[First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer]Mike Wenzel, Benedikt Hoeh, Jan Kasparek, et al.
Urologie (Heidelberg, Germany)|May 19, 2026
[Artificial intelligence in daily urological care: results of the AI barometer]Nicolas Carl, Frederik Wessels, Jonathan Jeutner, et al.
European Urology Open Science|June 17, 2025
Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate CancerMike Wenzel, Thomas Steuber, Carolin Siech, et al.
European Urology Focus|September 4, 2022
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysisPhilipp Mandel, Benedikt Hoeh, Mike Wenzel, et al.
Pageof 22